Monitoring Input and Output in CKD Stage 3

Primary Rationale for I&O Monitoring

CKD stage 3 patients have impaired ability to regulate fluid balance, with reduced nephron mass limiting compensatory mechanisms for both volume overload and depletion 1
Patients with CKD stage 3 are at highest risk for acute kidney injury (AKI) from volume perturbations, whether from dehydration or aggressive diuresis 1, 2
AKI superimposed on CKD accelerates progression to end-stage renal disease and increases mortality risk 2

Loop and thiazide diuretics require higher doses as GFR falls below 60 mL/min/1.73m², increasing the risk of excessive diuresis and renal deterioration 3
The greatest diuretic effect occurs within the first 1-3 days of therapy, causing significant electrolyte shifts and volume depletion that can precipitate AKI 3
Close monitoring is essential during the first 1-2 weeks of diuretic initiation or dose changes, when the risk of acute renal function decline is highest 3

Elevated central venous pressure from volume overload reduces glomerular filtration by decreasing the pressure gradient between afferent and efferent arterioles 1
Conversely, volume depletion reduces cardiac output and renal perfusion pressure, directly impairing kidney function 1
I&O monitoring helps identify these hemodynamic extremes before irreversible kidney damage occurs 1

During initiation or dose adjustment of diuretics, ACE inhibitors, or ARBs, close monitoring of I&O is recommended 3
During acute illness, particularly with fever, vomiting, or diarrhea, I&O monitoring should be intensified 1
In the presence of heart failure or other conditions causing hemodynamic instability, I&O monitoring is crucial 1
Optimal intravascular volume status should be maintained using isotonic crystalloids when volume expansion is needed 2